[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522590":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":11,"locations":29,"responsibleParty":43,"collaborators":11,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"BMS-986446","EXPERIMENTAL",null,[13],"Drug: BMS-986446",{"label":15,"type":10,"description":11,"interventionNames":16},"Placebo",[17],"Other: Placebo",[19,23],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Specified dose on specified days",[9],{"type":24,"name":15,"description":21,"armGroupLabels":25,"otherNames":11},"OTHER",[15],[27],{"name":5,"affiliation":5,"role":28},"STUDY_DIRECTOR",[30],{"facility":31,"status":11,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":11},"Local Institution - 0001","Cypress","California","90630","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-118.03729,33.81696,{"lat":41,"lon":40},{"type":44,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100522590","phase-1-a-study-to-evaluate-the-safety-tolerability-and-drug-levels-of-bms-986446-in-healthy-participants-and-healthy-participants-of-japanese-ethnicity-100522590",false,"NCT06084598","A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity","A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenously Administered BMS-986446 in Healthy Participants Including Healthy Participants of Japanese Ethnicity","Inclusion Criteria:\n\n* Participant must be of Japanese ethnicity (both biological parents are ethnically Japanese) for Part 1 and Part 2, Panel 2. No limitations on ethnicity apply to Part 2, Panel 1\n* Participant is healthy, without any significant abnormalities in medical history, physical examination, ECGs, or clinical laboratory assessments determinations, as assessed by the investigator\n* Body mass index (BMI) of at least 18 kg\u002Fm\\^2 but no more than 32 kg\u002Fm\\^2 at screening\n* Body weight between 45 kg and 110 kg\n\nExclusion Criteria:\n\n* Any clinically significant deviation from normal, as judged by the investigator\n* Any major surgery within 90 days of study drug administration\n* Participation in another interventional clinical trial concurrent with this study\n\nNote: Other protocol-defined inclusion\u002Fexclusion criteria apply",true,"ALL","18 Years","65 Years",{"count":57,"type":58},24,"ACTUAL","INTERVENTIONAL",[61],"PHASE1","The purpose of this study is to evaluate the safety, tolerability and drug levels of BMS-986446 in healthy participants including healthy participants of Japanese ethnicity.",[64],"Healthy Participants",[66,64,67,9,68],"Pharmacokinetics","Healthy Japanese Participants","PRX005","COMPLETED","2024-03-14",{"date":72,"type":58},"2024-03-15",{"date":74,"type":58},"2023-10-12",{"date":76,"type":58},"2024-03-08",{"name":5,"class":6},1]